<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295397</url>
  </required_header>
  <id_info>
    <org_study_id>iFAAM</org_study_id>
    <nct_id>NCT02295397</nct_id>
  </id_info>
  <brief_title>Integrated Approaches to Food Allergen and Allergy Risk Management</brief_title>
  <acronym>iFAAM</acronym>
  <official_title>Integrated Approaches to Food Allergen and Allergy Risk Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cork University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nebraska Lincoln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Hovedstadens Apotek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Madrileño de Salud, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with history of a food allergy to hazelnut, walnut or celeriac will undergo food&#xD;
      provocation with a dose of the allergenic food to which 5% of the respective food allergic&#xD;
      population (ED05) has been calculated to respond with allergic reactions (single shot study).&#xD;
&#xD;
      In patients with a hazelnut or peanut allergy a double-blind placebo controlled food&#xD;
      challenge with cookies containing either placebo or hazelnut and peanut respectively will be&#xD;
      performed to determine threshold levels eliciting an allergic reaction. The results for&#xD;
      threshold levels determined by cookie matrix will be compared to the results gained from the&#xD;
      EuroPrevall project (matrix comparison study).&#xD;
&#xD;
      In patients with a walnut allergy double-blind placebo controlled provocation with walnut&#xD;
      will be combined with the intake of proton pump inhibitor (PPI) or with placebo to assess the&#xD;
      impact of PPI on the threshold level and on the clinical manifestation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      single shot study, matrix comparison and walnut/PPI study&#xD;
&#xD;
        1. detailed case history, blood sampling and prick testing with different foods will&#xD;
           performed.&#xD;
&#xD;
        2. food provocation with a chocolate dessert meal containing either hazelnut, walnut or&#xD;
           celeriac (ED05) will be performed (single shot study) in patients with a positive case&#xD;
           history of an allergic reaction to either hazelnut, walnut or celeriac or with two meals&#xD;
           containing either placebo or hazelnut and peanut respectively in hazelnut and peanut&#xD;
           allergic patients or with three meals containing either placebo or walnut in walnut&#xD;
           allergic patients.&#xD;
&#xD;
        3. in patients with a negative single shot challenge an open provocation with native&#xD;
           hazelnut, walnut, celeriac will be performed unless the patients do not have had a&#xD;
           positive previous food provocation with the respective food. In patients with a negative&#xD;
           double-blind placebo-controlled food challenge an open provocation with hazelnut or&#xD;
           peanut or walnut will be performed to confirm tolerance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>numbers of patients reacting to ED05 in hazelnut, walnut, celeriac allergy</measure>
    <time_frame>November 2014 to February 2017, up to 27 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>numbers of patients reacting to a defined dose of peanut and hazelnut in titrated challenges</measure>
    <time_frame>November 2014 to February 2017, up to 27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the threshold dose of walnut that induces an allergic reaction after the intake of therapeutic doses of omeprazole Change in the severity of walnut allergy after the intake of therapeutic doses of omeprazole</measure>
    <time_frame>February 2015 to February 2017, up to 27 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>food provocation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open and placebo-controlled food challenges</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>food</intervention_name>
    <description>food provocation, skin testing, blood sampling</description>
    <arm_group_label>food provocation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  For single shot study: history of a hazelnut, walnut, celeriac allergy due to an&#xD;
             unequivocal accidental exposure with typical acute allergic reaction within the&#xD;
             preceding 2 years and positive allergen-specific skin prick test/specific&#xD;
             Immunoglobulin E or recent positive oral food challenge with hazel, walnut or celeriac&#xD;
             within previous 2 years in children &lt;16 years, but no time limit specified for adults&#xD;
&#xD;
          -  For matrix comparison study: history of peanut or hazelnut allergy&#xD;
&#xD;
          -  For walnut/PPI study: history of walnut allergy. The minimum age for this study is 18&#xD;
             years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe disease (heart, liver, kidney), acute febrile infection&#xD;
&#xD;
          -  Intake of Ketotifen (past 2 weeks), corticosteroids (past 2 weeks),&#xD;
             histamine-1-receptor blocker (past 3 days apart first generation past 7 days)&#xD;
&#xD;
          -  Anaphylactic reaction (past 4 weeks)&#xD;
&#xD;
          -  Uncontrolled bronchial asthma, forced expiratory volume &lt; 70% predicted&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Acute infection or allergy&#xD;
&#xD;
          -  Uncontrolled atopic dermatitis&#xD;
&#xD;
          -  Chronic urticaria&#xD;
&#xD;
          -  Mastocytosis&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clare Mills, Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>University Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy Unit, Department of Dermatology, University Hospital</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food provocation</keyword>
  <keyword>Matrix effect</keyword>
  <keyword>ED05</keyword>
  <keyword>Allergy</keyword>
  <keyword>Proton Pump Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

